Clinical Trials Directory

Trials / Completed

CompletedNCT03902392

Red Grape Polyphenol Oral Administration to Women Affected by Nickel-mediated Allergic Contact Dermatitis

Oral Human Administration of Red Grape Polyphenol in Nickel-mediated Allergic Contact Dermatitis: an in Vitro Study

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
50 (actual)
Sponsor
University of Bari · Academic / Other
Sex
Female
Age
25 Years – 60 Years
Healthy volunteers
Not accepted

Summary

Nickel (Ni)-mediated allergic contact dermatitis (ACD) is a very common disease worldwide. Our previous findings demonstrated that in vitro supplementation of polyphenols, extracted from seeds of red grape (Nero di Troia cultivar), to peripheral lymphomonocytes from Ni-mediated ACD patients could reduce release of T helper (h)1 \[interferon (IFN)-\] and Th2 \[interleukin (IL)-4\] cytokines, on the one hand. On the other hand, IL-10 (an anti-inflammatory cytokine) levels increased with a reduction of IL-17 (an inflammatory cytokine). Also levels of nitric oxide (NO) decreased in response to polyphenol pretreatment.

Detailed description

Nickel (Ni) is a transitional metal largely distributed in the environment whose continuous exposure is able to provoke local and systemic allergic contact dermatitis (ACD). Ni-mediated ACD is characterized by loss of epidermal integrity, urticaria/angioedema, flares, and itching, whose extent depends on many variables such as genetic, time of sensitization and environmental exposure.The aim of the present research is to verify whether the oral administration of polyphenols (NATUR-OX®) to patients with Ni-mediated ACD is able to modify immune parameters.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTNaturOx Group (A)Comparison between dietary supplement and placebo
OTHERPlacebo Group (B)Comparison between dietary supplement and placebo

Timeline

Start date
2018-04-16
Primary completion
2018-09-10
Completion
2018-10-31
First posted
2019-04-04
Last updated
2020-01-02
Results posted
2020-01-02

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT03902392. Inclusion in this directory is not an endorsement.